Zobrazeno 1 - 10
of 421
pro vyhledávání: '"Koen, Van Besien"'
Autor:
Terese C. Hammond, Marco A. Purbhoo, Sapana Kadel, Jerome Ritz, Sarah Nikiforow, Heather Daley, Kit Shaw, Koen van Besien, Alexandra Gomez-Arteaga, Don Stevens, Waldo Ortuzar, Xavier Michelet, Rachel Smith, Darrian Moskowitz, Reed Masakayan, Burcu Yigit, Shannon Boi, Kah Teong Soh, John Chamberland, Xin Song, Yu Qin, Ilya Mishchenko, Maurice Kirby, Valeriia Nasonenko, Alexa Buffa, Jennifer S. Buell, Dhan Chand, Marc van Dijk, Justin Stebbing, Mark A. Exley
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Invariant natural killer T (iNKT) cells, a unique T cell population, lend themselves for use as adoptive therapy due to diverse roles in orchestrating immune responses. Originally developed for use in cancer, agenT-797 is a donor-unrestricte
Externí odkaz:
https://doaj.org/article/d15d9c3789204f0f9cbf46c7c032881d
Autor:
Michael Daunov, Koen van Besien
Publikováno v:
Cells, Vol 13, Iss 21, p 1780 (2024)
Novel therapies such as CAR-T, BTK inhibitors and PD-1 inhibitors have changed the management of aggressive B-cell lymphomas. Nonetheless, these novel therapies have their own risk of late toxicities including second malignancies. They also create a
Externí odkaz:
https://doaj.org/article/15ef10504bdf4a7f8294968c7e0e2cb6
Autor:
Mayumi Sugita, Takahiro Yamazaki, Mohammad Alhomoud, Jérémie Martinet, Jean-Baptiste Latouche, Encouse Golden, Olivier Boyer, Koen Van Besien, Silvia C. Formenti, Lorenzo Galluzzi, Monica L. Guzman
Publikováno v:
Cell Death and Disease, Vol 14, Iss 5, Pp 1-8 (2023)
Abstract Autologous T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19 are approved for the treatment of various CD19+ hematological malignancies. While CAR T cells induce objective responses in a majority of patients,
Externí odkaz:
https://doaj.org/article/aa1f1d202091484a98064e5028973f74
Autor:
Boglarka Gyurkocza, Stuart Seropian, Hannah Choe, Mark Litzow, Camille Abboud, Nebu Koshy, Patrick Stiff, Benjamin Tomlinson, Sunil Abhyankar, James M Foran, Parameswaran Hari, George Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie Orozco, Katarzyna Jamieson, Margarida Silverman, Koen Van Besien, Michael Schuster, Arjun Law, Sameem Abedin, Karilyn Larkin, Scott Rowley, Pashna Munshi, Rachel Cook, Sebastian Mayer, Moshe Yair Levy, Hillard Lazarus, Brenda Sandmaier, Vijay Reddy, Jennifer Spross, Kathleen Mcnamara, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, John Pagel, Sergio Giralt, Avinash Desai, Rajneesh Nath
Publikováno v:
HemaSphere, Vol 7, p e2941723 (2023)
Externí odkaz:
https://doaj.org/article/40f049091be74a68a790fad6e86ff8be
Autor:
Mayumi Sugita, David C. Wilkes, Rohan Bareja, Kenneth W. Eng, Sarah Nataraj, Reyna A. Jimenez-Flores, LunBiao Yan, Jeanne Pauline De Leon, Jaclyn A. Croyle, Justin Kaner, Swathi Merugu, Sahil Sharma, Theresa Y. MacDonald, Zohal Noorzad, Palak Panchal, Danielle Pancirer, Shuhua Cheng, Jenny Z. Xiang, Luke Olson, Koen Van Besien, David S. Rickman, Susan Mathew, Wayne Tam, Mark A. Rubin, Himisha Beltran, Andrea Sboner, Duane C. Hassane, Gabriela Chiosis, Olivier Elemento, Gail J. Roboz, Juan Miguel Mosquera, Monica L. Guzman
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-10 (2021)
Abstract The epichaperome is a new cancer target composed of hyperconnected networks of chaperome members that facilitate cell survival. Cancers with an altered chaperone configuration may be susceptible to epichaperome inhibitors. We developed a flo
Externí odkaz:
https://doaj.org/article/9b26f08bf6d444edb5f3140c7fcddf4c
Autor:
Ajay Major, Justin Kline, Theodore G. Karrison, Paul A. S. Fishkin, Amy S. Kimball, Adam M. Petrich, Sreenivasa Nattam, Krishna Rao, Bethany G. Sleckman, Kenneth Cohen, Koen van Besien, Aaron P. Rapoport, Sonali M. Smith
Publikováno v:
Haematologica, Vol 107, Iss 7 (2021)
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the
Externí odkaz:
https://doaj.org/article/da69c238a67c488eac97c5b0995a9e46
Autor:
Yun Fan, Andrew S. Artz, Koen van Besien, Wendy Stock, Richard A. Larson, Olatoyosi Odenike, Lucy A. Godley, Justin Kline, John M. Cunningham, James L. LaBelle, Michael R. Bishop, Hongtao Liu
Publikováno v:
Experimental Hematology & Oncology, Vol 8, Iss 1, Pp 1-8 (2019)
Abstract Background Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT. Methods We analyzed retrospectively the outcomes of 65 consecutive patients who underwent a second HCT for dise
Externí odkaz:
https://doaj.org/article/c3a8d3ce41aa422d85163eeb2e9cfa36
Autor:
Ronald Levy, Joshua Brody, David L Porter, Sattva S Neelapu, Koen Van Besien, Michael Werner, Michael R Bishop, Mitchell S Cairo, Sherry Adkins, Stephen M Ansell, Jonathan W Friedberg, Justin P Kline
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, how
Externí odkaz:
https://doaj.org/article/2fb77ce0a5a54f93aaa50a040c2bdee0
Autor:
Alexandra Gomez-Arteaga, Nina Orfali, Michelle Pasciolla, Ayanna Baptiste, Inna Guindine, Jingmei Hsu, Jonathan Lin, Sebastian A. Mayer, Adrienne A. Phillips, Tsiporah B. Shore, Paul D. Simonson, Edward DiCarlo, Sung Yoon, Thangamani Muthukumar, Koen van Besien
Publikováno v:
Bone Marrow Transplantation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0627143ee964774e4d843cf16c7aa947
https://doi.org/10.1038/s41409-023-01981-x
https://doi.org/10.1038/s41409-023-01981-x
Autor:
Carlen A, Yuen, Jing-Mei, Hsu, Koen, Van Besien, Ran, Reshef, Fabio M, Iwamoto, Aya, Haggiagi, Benjamin, Liechty, Cenai, Zhang, Sarah F, Wesley, Rajiv, Magge
Publikováno v:
Journal of Immunotherapy. 45:254-262
Secondary central nervous system lymphoma (SCNSL) is associated with poor prognosis and new therapeutic approaches are needed. The pivotal trial that led to US Food and Drug Administration (FDA) approval of axicabtagene ciloleucel excluded patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b0dbb63cf018486b926fe7aa5abaf40
https://doi.org/10.1097/cji.0000000000000416
https://doi.org/10.1097/cji.0000000000000416